The unprecedented weakening of patent rights in the United States undermines necessary incentives for the discovery and development of innovative medicines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Grabowski, H. Nat. Rev. Drug Discov. 7, 479–488 (2008).
Herper, M. The truly staggering cost of inventing new drugs <http://www.forbes.com/sites/matthewherper/2012/02/10/the-truly-staggering-cost-of-inventing-new-drugs/> (10 February 2012).
Rader, R. Patent law and litigation abuse <http://mcsmith.blogs.com/files/rader-2013-ed-tex-bb-speech.pdf> (1 November 2013).
Kowalski, S. Patent literature and methodology: WHO model list of essential medicines <http://www.wto.org/english/tratop_e/trips_e/techsymp_feb11_e/kowalski_18.2.11_e.pdf>(18 February 2011).
KSR International Co. v. Teleflex Inc., 550 US 398 (2007).
Diamond v. Chakrabarty, 447 US 303 (1980).
Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 132 S.Ct. 1289 (2012).
Alice Corporation Pty. Ltd. v. CLS Bank International, 82 L.Ed.2d 296 (2014).
Association for Molecular Pathology et al., v. Myriad Genetics, Inc., 133 S.Ct. 2107 (2013).
eBay Inc. v. MercExchange, LLC, 547 US 388 (2006).
Merck KGaA v. Integra Lifesciences I, Ltd., 545 US 193 (2005).
Momenta Pharmaceuticals, Inc. v. Amphastar Pharmaceuticals, Inc., 686 F.3d 1348 (2012).
Limelight Networks, Inc. v. Akamai Technologies, Inc., 134 S.Ct. 2111 (2014).
35 USC Section 112.
Nautilus Inc. v. Biosig Instruments Inc., 134 S.Ct. 2120 (2014).
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 US 722 (2002).
MedImmune, Inc. v. Genentech, Inc., 549 US 118 (2007).
Rates Technology, Inc. v. Speakeasy, Inc., 685 F.3d 163 (2012).
Medtronic, Inc. v. Mirowski Family Ventures, LLC, 134 S.Ct. 843 (2014).
Microsoft Corp. v. i4i Limited Partnership, 131 S.Ct. 2238 (2011).
Kesselheim, A. N. Engl. J. Med. 363, 1855–1862 (2010).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Brougher, J., Linnik, K. Patents or patients: who loses?. Nat Biotechnol 32, 877–880 (2014). https://doi.org/10.1038/nbt.3005
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3005
This article is cited by
-
Relieving patent-eligibility barriers in biotech with a preparation or treatment method
Nature Biotechnology (2022)
-
An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market
Journal of Pharmaceutical Innovation (2022)